ConductScience.org, home

Comparison · NCT02914275-bde702f7

Seqirus QIV vs Comparator QIV: Number of Participants With Cellulitis-like Reactions

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Seqirus QIV vs Comparator QIV: Number of Participants With Cellulitis-like Reactions. Trial comparisons, record NCT02914275-bde702f7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02914275-bde702f7

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.00237wilson
Risk in group 20.001830.0003240.0103wilson
Risk difference, group 1 minus group 2-0.00183-0.01030.000975newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one fewer participant with the outcome on Seqirus QIV than on Comparator QIV545from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Seqirus QIVSubjects 6 months through 59 months of age who received Seqirus Quadrivalent Inactivated Influenza Vaccine.01,618OG000
Group 2Comparator QIVSubjects 6 months through 59 months of age who received Comparator Quadrivalent Inactivated Influenza Vaccine.1545OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Cellulitis-like Reactions
Description
Frequency of cellulitis-like reactions for at least 28 days after each vaccination dose
Time frame
Postvaccination (up to 28 days after each vaccination)
Population
The Solicited Safety Population comprises all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and had provided any evaluable data on solicited events.

Source ClinicalTrials.gov

Trial

Title
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
NCT number
NCT02914275
Phases
PHASE3
Conditions
Influenza, Human
Interventions
Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine
Lead sponsor
Seqirus
Results first posted
2019-01-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02914275-bde702f7